Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Centre for Immunobiology, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Br J Pharmacol. 2017 Nov;174(22):3898-3913. doi: 10.1111/bph.13818. Epub 2017 Jun 10.
Data from basic science experiments is overwhelmingly supportive of the causal role of immune-inflammatory response(s) at the core of atherosclerosis, and therefore, the theoretical potential to manipulate the inflammatory response to prevent cardiovascular events. However, extrapolation to humans requires care and we still lack definitive evidence to show that interfering in immune-inflammatory processes may safely lessen clinical atherosclerosis. In this review, we discuss key therapeutic targets in the treatment of vascular inflammation, placing basic research in a wider clinical perspective, as well as identifying outstanding questions.
This article is part of a themed section on Targeting Inflammation to Reduce Cardiovascular Disease Risk. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.22/issuetoc and http://onlinelibrary.wiley.com/doi/10.1111/bcp.v82.4/issuetoc.
未加标签：基础科学实验的数据压倒性地支持免疫炎症反应在动脉粥样硬化核心中的因果作用，因此，从理论上讲，有可能通过操纵炎症反应来预防心血管事件。然而，需要谨慎地将其推断到人类，我们仍然缺乏明确的证据表明干预免疫炎症过程可以安全地减轻临床动脉粥样硬化。在这篇综述中，我们讨论了血管炎症治疗中的关键治疗靶点，将基础研究置于更广泛的临床视角下，并确定了悬而未决的问题。
相关文章：本文是一个以“靶向炎症以降低心血管疾病风险”为主题的部分的一部分。要查看该部分中的其他文章，请访问 http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.22/issuetoc 和 http://onlinelibrary.wiley.com/doi/10.1111/bcp.v82.4/issuetoc。
Zotero 插件